BPG is committed to discovery and dissemination of knowledge
Articles in Press
9/25/2020 10:21:50 PM | Browse: 113 | Download: 326
| Category |
Oncology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yang-Yang Ma, Yin Leng, Yan-Li Xing, Hong-Mei Li, Ji-Bing Chen and Li-Zhi Niu |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| International Science Foundation of Affiliated Fuda Cancer Hospital, Jinan University |
Y2018-ZD-01 |
|
| Corresponding Author |
Li-Zhi Niu, MD, PhD, Chief Physician, Department of Interventional Radiology, Affiliated Fuda Cancer Hospital, Jinan University, No. 2 Tangde West Road, Tianhe District, Guangzhou 510665, Guangdong Province, China. niuboshi@fudahospital.com |
| Key Words |
Irreversible electroporation; Gemcitabine; Locally advanced pancreatic cancer; Overall survival; Progression free survival; Prognostic factors |
| Core Tip |
Locally advanced pancreatic cancer (LAPC) is a common malignant digestive system tumor with poor prognosis. Gemcitabine (GEM) is currently used as a first-line chemotherapy for treatment of LAPC; however, the overall outcome was poor. Irreversible electroporation (IRE) is a novel, non-thermal ablation technology that uses high voltage electrical pulses to induce pore formation, resulting in cell apoptosis. We found that GEM plus concurrent IRE resulted in significantly prolonging overall survival compared with chemotherapy alone. Therefore, GEM plus concurrent IRE has a synergistic effect on the clinical treatment of LAPC. |
| Citation |
Ma YY, Leng Y, Xing YL, Li HM, Chen JB, Niu LZ. Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer. World J Clin Cases 2020; 8(22): 5564-5575 |
 |
Received |
|
2020-08-12 09:07 |
|
Peer-Review Started |
|
2020-08-12 09:08 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-08-22 10:15 |
|
Revised |
|
2020-08-25 13:21 |
|
Second Decision |
|
2020-09-25 08:14 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-09-25 22:21 |
|
Articles in Press |
|
2020-09-25 22:21 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-10-07 13:05 |
|
Typeset the Manuscript |
|
2020-11-18 09:42 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
